Novavax (NVAX) Misses Q4 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Novavax (NVAX) Weakness Over Increased Spending is Unwarranted - FBR
March 1, 2016 7:22 AM ESTFBR Capital analyst, Vernon Bernardino, reiterated his Outperform rating as vaccine developer Novavax (NASDAQ: NVAX) reported 4Q15 financial results and presented highlights of its 2015 accomplishments: completion of enrollment ahead of guidance for the RSV vaccine Phase III study in elderly adults, completion of enrollment in the Phase II rollover study, and initiation of a second RSV vaccine Phase III study (maternal immunization of infants). The analyst believes... More
